| 000 | 01659 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513182650.0 | ||
| 264 | 0 | _c19990520 | |
| 008 | 199905s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/s002800050928 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKoda, R T | |
| 245 | 0 | 0 |
_aPhase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _c1999 |
||
| 300 |
_a489-96 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aThymidylate Synthase _xantagonists & inhibitors |
| 700 | 1 | _aGarcia, A A | |
| 700 | 1 | _aChatterjee, D J | |
| 700 | 1 | _aLi, W Y | |
| 700 | 1 | _aParimoo, D | |
| 700 | 1 | _aJeffers, S | |
| 700 | 1 | _aRogers, M | |
| 700 | 1 | _aLeichman, C G | |
| 700 | 1 | _aLeichman, L | |
| 700 | 1 | _aWu, E Y | |
| 700 | 1 | _aShetty, B V | |
| 700 | 1 | _aWebber, S | |
| 700 | 1 | _aClendinnin, N | |
| 700 | 1 | _aMuggia, F M | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 43 _gno. 6 _gp. 489-96 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002800050928 _zAvailable from publisher's website |
| 999 |
_c10280399 _d10280399 |
||